Sarepta Therapeutics (SRPT) Offering Seeing High Demand, Expected to Price at Modest Discount - Feurstein

September 22, 2016 3:40 PM EDT

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Sarepta Therapeutics (NASDAQ: SRPT) offering well oversubscribed, upsized and seen pricing at a modest discount to close. - Adam Feurstein.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Rumors, Trader Talk

Related Entities

Adam Feuerstein

Add Your Comment